First-line Treatment of Advanced/unresectable DDLPS

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions

Dedifferentiated LiposarcomaSoft Tissue Sarcoma (STS)

Interventions

DRUG

Liposomal Doxorubicin (Doxil)

30 mg/m2, d1, IV

DRUG

Apatinib

250 mg, qd

DRUG

Camrelizumab

200 mg, d1, IV

Trial Locations (1)

Fudan University, Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06694324 - First-line Treatment of Advanced/unresectable DDLPS | Biotech Hunter | Biotech Hunter